循环肿瘤细胞HER-2表达在胃腺癌靶向治疗中的应用

【】Gastric cancer is one of the common malignancies in the digestive system. Currently, HER-2 (Human Epidermal Growth Factor Receptor 2) has been identified as an important molecular marker in the treatment of gastric adenocarcinoma. However, the heterogeneity and variability of tumors limit the evaluation of HER-2 by tissue biopsy. Circulating tumor cells (CTCs) shed from primary or metastatic lesions into the blood can reflect the molecular features of tumor cells. Studies have shown that HER-2 expression can be detected in CTCs of gastric adenocarcinoma patients, and CTC detection can dynamically monitor the expression status of HER-2, compensating for the limitations of single-point tissue sampling. Therefore, this article will review the predictive value of CTC-HER-2 detection in evaluating the efficacy of targeted therapy in gastric adenocarcinoma patients and the latest advancements in clinical research.